Skip to main content
TipRanks
Go Ultimate75% OFF

China Traditional Chinese Medicine Holdings Co (CHIZF) AI Stock Analysis

8 Followers
CHIZF

China Traditional Chinese Medicine Holdings Co

(Other OTC:CHIZF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low leverage and financial flexibilityFalling debt relative to equity gives the company greater financial flexibility over the next several quarters. Lower leverage reduces refinancing pressure and leaves more capacity to support operations, manage industry volatility, or fund selective investment without relying heavily on additional borrowing.
Negative Factors
Profitability deterioration and 2025 lossThe shift from sustained profits to a 2025 net loss is a material deterioration in earnings quality and reduces the company’s ability to compound shareholder value. Continued losses could constrain reinvestment and weaken the effectiveness of its otherwise conservative balance sheet.

China Traditional Chinese Medicine Holdings Co (CHIZF) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%CHIZF-40.29%SPY+14.28%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$821.34M
Dividend Yield
0.28%
Average Volume (3M)
―
Price to Earnings (P/E)
-4.1
Beta (1Y)
0.33
Revenue Growth
-16.02%
EPS Growth
-297.26%
Country
US
Employees
14,846
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

China Traditional Chinese Medicine Holdings Co Business Overview & Revenue Model

Company Description

China Traditional Chinese Medicine Holdings Co. Limited functions as an investment holding company, primarily focusing on the research, development, and sale of traditional Chinese medicine and other pharmaceutical goods across the People's Republic...

China Traditional Chinese Medicine Holdings Co Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CHIZF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:6896HK:689665NeutralHKD 1.42B5.6516.70%17.99%-5.37%-18.03%
HK:0897HK:089759NeutralHKD 395.61M102.780.34%―-8.30%-44.44%
HK:0874HK:087457NeutralHKD 35.45B14.675.57%6.73%6.00%-23.05%
HK:0512HK:051255NeutralHKD 15.72B13.636.61%3.87%7.35%-45.49%
HK:0719HK:071954NeutralHKD 8.52B38.304.32%3.22%-0.52%-37.60%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%CHIZFHK:0874HK:0897HK:0512HK:6896HK:0719Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CHIZF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CHIZFChina Traditional Chinese Medicine Holdings Co 0.16-0.11-40.29%
HK:0874Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H12.82-6.27-32.83%
HK:0897Wai Yuen Tong Medicine Holdings Limited0.37-0.09-19.57%
HK:0512Grand Pharmaceutical Group Limited4.37-4.10-48.38%
HK:6896Golden Throat Holdings Group Co Ltd1.89-1.22-39.25%
HK:0719Shandong Xinhua Pharmaceutical Company Limited Class H5.36-1.65-23.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.